<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373710</url>
  </required_header>
  <id_info>
    <org_study_id>09/501/M</org_study_id>
    <secondary_id>2009-017218-63</secondary_id>
    <nct_id>NCT01373710</nct_id>
  </id_info>
  <brief_title>Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis</brief_title>
  <acronym>HIT</acronym>
  <official_title>Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

      Phase I: To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated
      by intrathecal or intraventricular route to reach a intra CSF target concentration (30 µg/mL)
      near the conventional therapeutic concentration and depending on the dose-limiting toxicity
      (DLT)

      Phase II: Determination of antitumor activity trastuzumab when administrated by IT or
      intra-ventricular in terms of neurological progression-free survival at 2 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I: Secondary Outcome Measures:

      Recommended dose (RD will be used in Phase II) Toxicity during treatment Clinical response to
      specific neurologic symptoms Time to neurologic progression Biological response: CSF
      cellularity and protein concentration Radiological response: cerebrospinal meningitis and
      neuraxis RMI Impact on quality of life Impact on survival (overall survival, survival without
      neurological progression, progression-free survival) Pharmacokinetics: dose of trastuzumab in
      CSF and plasma FCGR3A Genetic status influence on efficacy trastuzumab in metastatic breast
      cancer

      Phase II: Secondary Outcome Measures :

      Toxicity during treatment Clinical response to specific neurologic symptoms Time to
      neurologic progression Biological response: CSF cellularity and protein concentration
      Radiological response: cerebrospinal meningitis and neuraxis MRI Impact on quality of life
      Impact on survival (overall survival, survival without neurological progression,
      progression-free survival) Pharmacokinetics: dose of trastuzumab in CSF and plasma
      (confirmation of phase I data with 5 patients) FCGR3A Genetic status influence on efficacy
      trastuzumab in metastatic breast cancer
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 19, 2011</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I : To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route.</measure>
    <time_frame>2 months</time_frame>
    <description>Phase I : To determine the Trastuzumab maximimum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route to reach a intra CSF target concentration (30 µg/mL) near the conventional therapeutic concentration and depending on the dose-limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I : Recommended dose (RD will be used in Phase II)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I&amp;II : Toxicity during treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Issued the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 National Cancer Institute (NCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neurologic progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response: CSF cellularity and protein concentration</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response: cerebrospinal meningitis and neuraxis MRI</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on survival (overall survival, survival without neurological progression, progression-free survival)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: dose of trastuzumab in CSF and plasma</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FCGR3A Genetic status influence on efficacy trastuzumab in metastatic breast cancer</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II : Determination of antitumor activity trastuzumab when administrated by IT or intra-ventricular in terms of neurological progression free survival at 2 months</measure>
    <time_frame>2 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Carcinomatous Meningitis</condition>
  <arm_group>
    <arm_group_label>Trastuzumab intrathecal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg</description>
    <arm_group_label>Trastuzumab intrathecal</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metaplastic Infiltrating adenocarcinoma of the breast

          -  HER2 Overexpression by IHC and / or amplification (FISH and or ICHS)

          -  Positive diagnosis of neoplastic meningitis: positive CSF cytology (obtained within 28
             days before inclusion) AND / OR clinical symptoms of neoplastic meningitis and aspect
             of tumoral meningitis on MRI

          -  Brain metastases are allowed without prior treatment, if they are asymptomatics and
             without engagement. In cases of symptomatic brain metastases, subjects could be
             included only if surgery and / or radiotherapy (stereotactic or in toto) were
             performed and if the cerebral metastatic localization allow IT or intra-ventricular
             treatment. The last radiotherapy session or the surgery must have been done 3 weeks
             before.

          -  Aged 18 years old or more

          -  Male and female

          -  Life expectancy more than 2 months

          -  Satisfactory Cardiac function: left ventricular ejection fraction (LVEF) determined by
             ultrasound scan or myocardial scintigraphy

          -  Adequate Biological functions 14 days before inclusion, according to the criteria
             below: Neutrophils &gt; 1.0 x 109/L, Hemoglobin &gt; 9.0 g/dL (+ transfusion if
             needed,Platelets &gt; 50 x 109/L,Bilirubin &lt; 3 x N, ALT &amp; AST &lt; 10 x N, Creatinine &lt; 2.0
             mg/dL, Clearance &gt; 25 mL/min (Cockcroft and Gault formula), Prothrombin time &gt; 70 %,
             Kaolin cephalin coagulation time &lt; 1.5 x N.

          -  Women of childbearing potential, must take adequate birth control measure during the
             study period and must have a negative pregnancy test (BetaHCG serum)

          -  The subjects must perform all evaluations of pre-inclusion, as provided by the
             protocol

          -  Signed written inform consent

        Exclusion Criteria:

          -  CSF circulation disorders suspected on MRI brain (obstructive hydrocephalus) or
             medullar (obstacle) with, in case of a focal radiotherapy on obstructive lesion,
             checking the restoration of transit traffic by isotope CSF

          -  Anti-coagulant effective dose treatment when trastuzumab administration by lumbar
             puncture

          -  Patient on Lapatinib (wash out&gt; 2 weeks from the date of first dose intrathecal
             trastuzumab)

          -  Known or suspected trastuzumab allergy

          -  Contraindications of trastuzumab administration, including cardiac diseases: LVEF
             &lt;laboratory lower limit of normal or any other heart condition which would expose the
             subject to an unreasonable risk if he were to participate in the study

          -  Severe toxicity unresolved or unstable related to another previous study restricted
             drug and / or a cancer treatment

          -  Ventriculoperitoneal or atrial shunting excepted if the valve could be turn off
             (on-off switch) and the patient can stand it during 6 h after each injection of
             trastuzumab

          -  Dementia, altered mental status or psychiatric condition that would prevent the
             subject to understand or give informed consent

          -  Pre-existing severe cerebrovascular disease, such as stroke in a major vessel,
             vasculitis in the central nervous system or malignant hypertension

          -  Uncontrolled infection

          -  Participation in a clinical study with an experimental molecule

          -  No affiliation to a Social insurance (beneficiary or assignee)

          -  Pregnant women, breastfeeding or of childbearing age not taking contraceptive

          -  Subject unable to make follow up schedule

          -  Persons deprived of liberty or under guardianship (including curators)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Gutierrez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie - Hopital Rene Huguenin - Saint-Cloud - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>François Baclesse Center</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rene Huguenin Hospital</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Haut De Seine</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Claudius Regaud Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Léon Bérard Center</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Univesitaire du Cancer de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adverse Reaction to Trastuzumab Administered by intrathecal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

